Choosing Among PARP Inhibitors as Maintenance Therapy in Ovarian Cancer

Videos
Amina Ahmed, MD
Associate Chief Medical Officer
Division Gynecology, Dept OBGYN
Cancer Center of Rush University Medical Center
Chicago, IL
Ali McBride, PharmD, MS, BCPS
Clinical Coordinator
The University of Arizona Cancer Center
Tucson, AZ
Paula Anastasia, RN, MN, AOCN
GYN Oncology Clinical Nurse Specialist
UCLA Health
Los Angeles, CA
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, describe their experiences in the use of niraparib, olaparib, and rucaparib as first-line maintenance therapy in ovarian cancer.

Related Items


Subscribe to The Oncology Nurse-APN/PA

To sign up for our newsletter or print publications, enter your contact information below.

I'd like to receive: